Calliditas Therapeutics AB (Calliditas Therapeutics AB) PS Ratio

Array ( [0] => - [1] => - [2] => - [3] => - [4] => 15.13 [5] => 7,347.37 [6] => 25.00 [7] => 6.11 [8] => 5.65 )

Calliditas Therapeutics AB Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
PS Ratio						15.13	7,347.37	25.00	6.11	5.65

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
PS Ratio																11.07	6.11	4.83	5.25	5.65

For the Biotechnology subindustry, Calliditas Therapeutics AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's PS Ratio falls into.

Calliditas Therapeutics AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Calliditas Therapeutics AB's PS Ratio for today is calculated as

Calliditas Therapeutics AB's Share Price of today is $18.70.
Calliditas Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.56.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

The Revenue here is for the trailing 12 months.

Calliditas Therapeutics AB  (NAS:CALT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.

Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.

Calliditas Therapeutics AB PS Ratio Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description